Urology | Home | MIMS Malaysia

AbobotulinumtoxinA casts tinge of hope for erectile dysfunction

Audrey Abella, Yesterday

The addition of abobotulinumtoxinA (aboBTX-A) – one of three commercial preparations of botulinum toxin (BTX) type A – to phosphodiesterase type 5 inhibitors (PDE5-Is) or prostaglandin E1 (PGE1) led to favourable outcomes in men with erectile dysfunction (ED), a new study shows.

Ketorolac effective, safe for postoperative catheter-related bladder discomfort

Audrey Abella, 2 days ago

Ketorolac, a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygenase inhibitor, is effective and safe in preventing catheter-related bladder discomfort (CRBD) in men who have undergone robot-assisted laparoscopic radical prostatectomy (RALP), highlighting its potential role in postoperative CRBD management, a study shows.

New penile extender hits a home run for Peyronie’s disease

Audrey Abella, 3 days ago

Use of the novel penile traction therapy (PTT) device, RestoreX, in combination with injections of collagenase Clostridium histolyticum (CCH), led to significant improvements in penile deformities due to Peyronie’s disease (PD), a study has shown.

Naftopidil helps facilitate small ureteral stone passage in men

Audrey Abella, 5 days ago

The alpha-1 blocker naftopidil facilitated spontaneous expulsion of small ureteral stones in men, highlighting its potential in medical expulsive therapy (MET) for individuals with ureteral stones, a Japanese study has shown.

Low muscle mass ups risk of recurrence, death after radical prostatectomy in prostate cancer patients

6 days ago

There appears to be an association between low muscle mass and increased risks of recurrence and mortality in patients who undergo radical prostatectomy of prostate cancer regardless of the body mass index (BMI), suggests a recent study.

Robotic operation trumps laparoscopy in men who underwent previous bladder outlet surgery

17 Aug 2019

Robot-assisted radical prostatectomy offers superior outcomes over the laparoscopic technique for patients who underwent previous bladder outlet surgery of benign prostatic hyperplasia, according to a systematic review and pooled analysis of comparative studies.

Uroselective α1A-AR antagonist: A promising agent for the management of BPH

15 Mar 2019

At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.

Nocturia: An inside view on key causes and principles of management

02 Nov 2017

Nocturia is the most prevalent of the lower urinary tract symptoms (LUTS) and can cause a significant negative impact on an individual’s quality of life if left untreated.1,2 In a meeting held at University Malaya Medical Centre, Associate Professor Dr Ong Teng Aik shared his insights on the management of nocturia.

Research sheds light on PARP inhibitor use in mCRPC

Jackey Suen, 06 Mar 2019

The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.

Immune-checkpoint inhibitors changing the landscape of bladder cancer management

Dr. Joseph Delano Fule Robles, 04 Mar 2019

Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.

Robot-assisted radical cystectomy comparable to open cystectomy for urologic cancers

Dr. Joseph Delano Fule Robles, 22 Feb 2019

Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.

Prostate cancer biomarker research gains momentum, but challenges remain

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Nanotechnology structured water shows potential for ED treatment

Audrey Abella, 11 May 2018

Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.

Vibegron shows potential as OAB treatment

Audrey Abella, 30 Apr 2018

The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

No benefit to targeted antibiotic prophylaxis before TRUS-guided prostate biopsy

Roshini Claire Anthony, 23 Apr 2018

Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.